GlassScriptPhysician profile
Matthew Eric Viernes
NPI 1730158650
$11,195.49
in general payments reported to CMS, 2019-2025
34 companies · $2,393 in 2025
The $2,393 reported for 2025 was more than what 83% of Gastroenterology (Internal Medicine) providers received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,533 · 2020: $332 · 2021: $922 · 2022: $1,762 · 2023: $2,082 · 2024: $2,172 · 2025: $2,393.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,554 · Education: $93.17.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,553.73 |
| Education | $93.17 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $3,471.91 | 2019-2025 | Skyrizi, Rinvoq, Linzess |
| Janssen Biotech, INC. | $1,615.18 | 2019-2025 | Stelara, Tremfya, Simponi |
| Takeda Pharmaceuticals U.S.A., INC. | $1,395.04 | 2019-2025 | Entyvio, Eohilia |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $704.15 | 2019-2025 | Xifaxan, Trulance, Plenvu |
| Gilead Sciences, INC. | $500.19 | 2019-2025 | |
| Pfizer INC. | $461.72 | 2019-2025 | |
| Celgene Corporation | $323.60 | 2021-2023 | Zeposia |
| Madrigal Pharmaceuticals | $316.68 | 2024-2025 | Rezdiffra, Resmetirom |
| Lilly USA, LLC | $307.46 | 2024-2025 | Omvoh |
| Merck Sharp & Dohme LLC | $296.92 | 2019-2024 | Dificid, Pifeltro |
| Intercept Pharmaceuticals, INC. | $277.56 | 2019-2025 | Ocaliva |
| Regeneron Healthcare Solutions, INC. | $266.60 | 2022-2025 | Dupixent |
| Allergan, INC. | $170.09 | 2019 | |
| Enterra Medical, INC. | $168.01 | 2022-2025 | |
| Genzyme Corporation | $122.28 | 2023-2025 |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ferring Pharmaceuticals INC. | $103.68 | 2019-2022 | |
| Qol Medical, LLC | $102.42 | 2019-2021 | |
| Amgen INC. | $89.88 | 2021 | |
| Phathom Pharmaceuticals, INC. | $83.73 | 2024-2025 | Voquezna |
| Braintree Laboratories, INC. | $68.54 | 2019-2025 | Suflave, Sutab |
| Shionogi INC | $42.23 | 2019 | |
| Ironwood Pharmaceuticals, INC | $39.04 | 2020-2022 | |
| Alfasigma USA, INC. | $37.06 | 2020 | |
| Redhill Biopharma INC. | $32.66 | 2020-2021 | |
| Celltrion USA INC. | $29.00 | 2024-2025 | Vegzelma, Zymfentra |
| Ardelyx, INC. | $25.22 | 2023 | Ibsrela |
| Novo Nordisk INC | $24.35 | 2025 | Wegovy |
| Ucb, INC. | $22.17 | 2020 | |
| Intra-Sana Laboratories | $21.02 | 2021 | |
| Vivus LLC | $17.10 | 2024 | Qsymia |
| Alnylam Pharmaceuticals INC. | $17.03 | 2021 | |
| Azurity Pharmaceuticals, INC. | $15.34 | 2025 | Sutab |
| Evoke Pharma, INC. | $14.18 | 2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $13.45 | 2023 | Cyltezo |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Matthew Viernes listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.